Last reviewed · How we verify
Tasigna
At a glance
| Generic name | Tasigna |
|---|---|
| Also known as | Nilotinib, AMN107 |
| Sponsor | XSpray Microparticles |
| Target | Ferrochelatase, mitochondrial, Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, Serine/threonine-protein kinase MRCK beta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Chronic Myelocytic Leukemia Accelerated Phase
- Chronic phase chronic myeloid leukemia
- Philadelphia Chromosome Positive Chronic Myelocytic Leukemia
Common side effects
- Rash
- Pruritus
- Nausea
- Headache
- Fatigue
- Vomiting
- Diarrhea
- Cough
- Constipation
- Arthralgia
- Nasopharyngitis
- Pyrexia
Serious adverse events
- Thrombocytopenia
- Neutropenia
- Anemia
- Febrile Neutropenia
- Pneumonia
- Leukopenia
- Intracranial Hemorrhage
- Elevated Lipase
- QTcF Prolongation >60 msec
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (PHASE2)
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel (PHASE2)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (PHASE2)
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (PHASE3)
- Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib (PHASE2)
- Asciminib Roll-over Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tasigna CI brief — competitive landscape report
- Tasigna updates RSS · CI watch RSS
- XSpray Microparticles portfolio CI